

SCIENTIFIC REPORTS



OPEN

Gata4 is critical to maintain gut barrier function and mucosal integrity following epithelial injury

David Lepage¹, Élise Bélanger¹, Christine Jones¹, Sarah Tremblay², Joannie M. Allaire¹, Joannie Bruneau¹, Claude Asselin¹, Nathalie Perreault¹, Alfredo Menendez², Fernand-Pierre Gendron¹ & Francois Boudreau¹

Received: 15 June 2016
Accepted: 20 October 2016
Published: 09 November 2016

The intestinal epithelial barrier is critical to limit potential harmful consequences from exposure to deleterious luminal contents on the organism. Although this barrier is functionally important along the entire gut, specific regional regulatory mechanisms involved in the maintenance of this barrier are poorly defined. Herein, we identified *Gata4* as a crucial regulator of barrier integrity in the mouse proximal intestinal epithelium. Conditional deletion of *Gata4* in the intestine led to a drastic increase in claudin-2 expression that was associated with an important increase of gut barrier permeability without causing overt spontaneous inflammation. Administration of indomethacin, a non-steroidal anti-inflammatory drug (NSAID) that causes enteritis, led to rapid and restricted proximal small intestinal injuries in *Gata4* mutant mice as opposed to control mice. Comparative analysis of gene transcript profiles from indomethacin-challenged control and *Gata4* mutant mice identified defects in epithelial cell survival, inflammatory cell recruitment and tissue repair mechanisms. Altogether, these observations identify *Gata4* as a novel crucial regulator of the intestinal epithelial barrier and as a critical epithelial transcription factor implicated in the maintenance of proximal intestinal mucosal integrity after injury.

The small intestinal epithelium is a dynamic system that constantly and rapidly regenerates throughout individual life. The continuous production of intestinal epithelial cells is ensured by crypt based columnar stem cells capable of producing progenitors that will differentiate upon distinct integrated molecular programs responsible for the specification of the main cell lineages including enterocytes, goblet, enteroendocrine and Paneth cells¹. Tight regulation of this process is crucial in order to ensure basic epithelium functions and the integrity of the intestinal barrier that protects against potential harmful luminal content². Toward this end, the intestinal epithelium maintains a permissive mechanical barrier function strictly dependent on apical junctional complexes between epithelial cells that include tight junctions and adherens junctions³. Tight junctions localize to the apical end of the lateral surface of adjacent epithelial cells and consist of several transmembrane proteins such as occludin and claudins that mediate adhesion and barrier formation as well as paracellular diffusion⁴. The exact molecular composition and relative expression level of claudins can modulate the overall properties of tight junctions. While most claudins are recognized to maintain strong junctional integrity, several evidences support an opposite role for the claudin-2 member⁵. When overexpressed in Madin-Darby canine kidney (MDCK) epithelial cells, claudin-2 was able to increase tight junction paracellular cation permeability⁶. In addition, knockout mice for *Cldn2* display decreased transepithelial conductance of the small intestinal epithelium⁷. Thus, claudin-2 is functionally associated with tight junction leakiness and its modulation upon biological processes or pathological conditions correlates well with decreased intestinal barrier integrity^{8,9}.

A subset of transcriptional regulators has been reported to promote intestinal epithelial cell polarization and differentiation. *Cdx2* was originally identified as a master regulator of this process in cultured cells¹⁰. With the use of conditional mouse knockout strategies, *Cdx2* has been further established as being crucial for intestinal epithelial cell fate adoption as well as apical-basolateral polarity^{11,12}. Both *Hnf4 α* and *Hnf1 α* were also identified to modulate cell polarization and differentiation both in culture¹³ and in the mouse intestinal epithelium¹⁴. *Gata4*,

¹Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Quebec, Canada. ²Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Quebec, Canada. Correspondence and requests for materials should be addressed to F.B. (email: francois.boudreau@usherbrooke.ca)




Figure 1. Conditional deletion of *Gata4* in the mouse intestinal epithelium negatively impacts mucosal barrier integrity. (a) Total RNA was isolated from the jejunum, ileum and colon of control and *Gata4*^{ΔIEC} mice (n = 3–4 per group) and RT-qPCR was performed to quantify *Gata4* gene transcripts. (b) Electron microscopic analysis of jejunum epithelial cells from control and *Gata4*^{ΔIEC} mice. White arrows indicate apical tight junctions. (c) Intestinal permeability was assessed by measuring circulating FITC-dextran levels 4 h following gavage of control and *Gata4*^{ΔIEC} mice (n = 8–10 per group). ****P* < 0.001 (Student-t test). (d) Control and *Gata4*^{ΔIEC} mice were orally infected with *Salmonella typhimurium* SB103 and bacterial counts were done in liver and spleen (n = 5–6 per group). **P* < 0.05 (Mann-Whitney test).

a member of zinc finger-containing GATA transcription factor family, regulates several intestinal epithelial genes in combination with Cdx2, Hnf4α and Hnf1α^{15,16}. The expression of *Gata4* in the intestine is mostly restricted to the proximal small intestinal epithelium and the generation of *Gata4*-conditional intestinal epithelial knockout mouse models elucidated some of its functions in this context. Indeed, *Gata4* regulates specific gene networks along the anterior-caudal axis of the gut epithelium by activating jejunum specific genes^{17,18} and by repressing the ileal gene expression program^{19,20}. Intestinal deletion of *Gata4* also affects lipid metabolism¹⁷, induces bile acid absorption from the jejunum²¹ and was recently proposed to act as a mediator of the gut microbiota-dependent negative effects on jejunum bile acid absorption²². *Gata4* was also recently shown to regulate intestinal epithelial expression of regenerating islet derived family members (REG)²³ for which some members are involved in defense mechanisms and epithelial maintenance of the small intestinal epithelium^{24,25}.

Here we investigated the potential role for *Gata4* in regulating intestinal mucosal barrier integrity. Our findings support a crucial function for this transcriptional regulator in actively repressing the leaky tight junction claudin-2 component, maintaining gut barrier properties and also preventing acute mucosal injury in the proximal small intestine.

Results

***Gata4* intestinal epithelial deletion impacts functional barrier integrity and regulation of claudin-2 expression.** *Gata4* intestinal epithelial conditional knockout mice were generated from previously characterized *Gata4*^{loxP} allele mice²⁶ with *Villin-Cre* transgenic mice that exclusively express Cre in the intestinal epithelium²⁷. *Gata4*^{ΔIEC} mice were significantly deleted for *Gata4* gene transcript expression in the jejunum when compared to control littermates (Fig. 1a), while weak expression was recorded in the most distal portion of the ileum and no expression in the colon of control mice, as originally reported¹⁸. *Gata4* deletion was also confirmed at the level of *Gata4* protein expression, as visualized by immunofluorescence (data not shown)²³. Since the overall expression of *Gata4* was substantially more important in the proximal intestine than distally, we focused on the proximal region of the small intestine. Electron microscopy was first performed to monitor the overall integrity of enterocytes in absence of *Gata4*. Epithelial cells from control mice displayed typical junctional complexes between cells with sealed tight junction structures at the enterocytes apex (Fig. 1b). Although overall epithelial cell ultrastructures were similar among *Gata4*^{ΔIEC} and control mice, tight junctions systematically appeared less

well defined in *Gata4*^{ΔIEC} mice when compared to controls (Fig. 1b). Since it was difficult to quantitatively evaluate potential tight junction defects based on ultrastructure analysis, intestinal permeability was next assessed after *Gata4*^{ΔIEC} and control groups of mice were gavaged with FITC-labeled dextran. Detection of FITC concentrations in the serum of *Gata4*^{ΔIEC} mice was significantly increased more than 18.2-fold ($P < 0.001$) when compared to littermate controls (Fig. 1c). To further understand the physiological impact of such increases in mucosal permeability and to determine whether it results in increased translocation of intestinal bacteria, mice were orally infected with the *Salmonella typhimurium* invasion-deficient strain SB103. Due to a mutation in the *invA* gene, this strain is unable to invade enterocytes^{28,29} and therefore, its translocation to the mucosa solely depends on other mechanisms (e. g., increased epithelial permeability). Oral infections of *Gata4*^{ΔIEC} mice with *Salmonella typhimurium* SB103 led to significant increases in liver (29.3-fold; $P < 0.05$) and spleen (26.9-fold; $P < 0.05$) colonization when compared to infected controls (Fig. 1d). Taken together, these observations support the existence of intestinal barrier defects in the absence of *Gata4*.

To explore by which mechanisms *Gata4* could transcriptionally influence epithelial permeability, gene transcript expression of several molecules functionally involved in the formation of junctional complexes were quantified in *Gata4*^{ΔIEC} and control mouse jejunum samples (Supplementary Table 1). From this analysis, claudin-2 was found to be the most drastically modulated transcript with a significant 6.6-fold increase ($P < 0.0001$) in *Gata4*^{ΔIEC} mice in comparison to controls (Fig. 2a). This induction of expression was also reflected at the protein level as determined by Western blot on total jejunum extracts (Fig. 2b) and immunofluorescence on jejunum sections (Fig. 2c). Interestingly, claudin-2 was strongly detected at the apex of crypt and differentiated enterocytes in *Gata4*^{ΔIEC} mice while mostly restricted to crypt epithelial cells in control mice (Fig. 2c). *Gata4* was previously identified to positively regulate transcription of the human *CLDN2* gene promoter³⁰. Sequence analysis of the 5'-flanking region of the murine *Cldn2* gene predicted three putative GATA elements for which one was located in the TSS vicinity of the promoter (Fig. 2d). ChIP experiments were then conducted on mouse jejunum isolated from control and *Gata4*^{ΔIEC} mice. Antibody specific for *Gata4* was able to precipitate mouse wild-type jejunum chromatin encompassing the three predicted GATA-binding sites of the murine *Cldn2* gene but failed to precipitate mouse *Gata4*^{ΔIEC} jejunum chromatin under the same conditions (Fig. 2e–g). To further monitor whether loss of *Gata4* interaction with the *Cldn2* gene could be functionally linked to active chromatin, histone modification methylation marks of the *Cldn2* gene were quantified in the presence or absence of *Gata4*. Pull-down of H3K4me3, that labels active chromatin, showed a drastic enrichment of mouse *Gata4*^{ΔIEC} jejunum chromatin in the vicinity of *Cldn2* GATA interacting sites (Fig. 2h). Coincidentally, H3K27me3, a repressive histone modification marker showed a decreased association with *Gata4*^{ΔIEC} jejunum chromatin surrounding *Cldn2* GATA binding sites (Fig. 2i). Taken together, these observations support a direct role for *Gata4* in repressing *Cldn2* gene transcription in mouse jejunum epithelial cells.

Impaired intestinal mucosal barrier integrity in *Gata4*^{ΔIEC} mice does not lead to spontaneous intestinal inflammation. Histological observations of the small intestine from *Gata4*^{ΔIEC} mice did not reveal signs of inflammation as late as 1 year of age (Fig. 3a,b). A mouse inflammatory response qPCR array performed on jejunum extracts did not indicate important inflammation related changes when *Gata4*^{ΔIEC} mice were compared to controls (Supplementary Table 2). A careful examination of the jejunum distribution of inflammatory cells was next compared between *Gata4*^{ΔIEC} and control mice. While no significant modification in the total number of CD3 positive cells per villus was noted between *Gata4*^{ΔIEC} and control mice, a modest but significant increase in the ratio of CD3-positive intraepithelial lymphocytes (IELs) (1.4 fold; $P < 0.0001$) was observed in the mucosa of *Gata4*^{ΔIEC} mice when compared to controls (Fig. 3a–c). A modest but significant decrease in the number of CD68-labeled macrophages per villus (1.5 fold; $P < 0.001$) was also observed in the jejunum of *Gata4*^{ΔIEC} mice when compared to controls (Fig. 3d,e). These observations suggest that increased barrier permeability in non-inflammatory challenged *Gata4*^{ΔIEC} mice modestly affected their jejunum mucosal immunity and do not spontaneously lead to intestinal inflammation.

***Gata4*^{ΔIEC} mice are severely sensitive to indomethacin-induced small intestinal injury response.** Indomethacin-induced small intestinal inflammation model was next used to investigate whether absence of jejunum *Gata4* expression could sensitize mice to injury insults. Control and *Gata4*^{ΔIEC} mice were injected with a single dose of indomethacin (10 mg/kg) and rapidly sacrificed 24 h after treatment due to the severity of *Gata4*^{ΔIEC} mice response. Histological assessment of the small intestinal mucosa following this treatment revealed drastic villi regression in the duodenum of *Gata4*^{ΔIEC} mice (Fig. 4b,h) as opposed to controls (Fig. 4a,g). This effect was also observed in the jejunum of *Gata4*^{ΔIEC} mice (Fig. 4d,j) when compared to controls (Fig. 4c,i). Interestingly, ileum histology was similar between *Gata4*^{ΔIEC} (Fig. 4f) and control (Fig. 4e) treated groups. We next investigated whether these changes in intestinal epithelium integrity can relate to proliferation defects of progenitor crypt epithelial cells. PCNA labeling on intestinal sections of *Gata4*^{ΔIEC} and control indomethacin-treated mice was relatively constant among the crypts of both control (Supplementary Fig. 1a) and *Gata4*^{ΔIEC} (Supplementary Fig. 1b) treated mice, without an overall significant change in the ratio of labeled cells per number of crypt cells (Supplementary Fig. 1c). This observation suggests that indomethacin-induced small intestinal mucosal injuries in absence of *Gata4* were not originating from alterations of the epithelial cell proliferative pools but rather defects in epithelial cell viability or adherence.

In order to clarify the nature of the signals linked with increased mucosal injury in the absence of *Gata4*, a gene expression profiling was next performed. This analysis was done in biological triplicate with RNA isolated from the jejunum of indomethacin-treated control and indomethacin-treated *Gata4*^{ΔIEC} mice. The Illumina Mouse WG-6 v2.0 Expression Bead chip that contains more than 45,200 transcripts from the mouse genome was utilized to screen for mRNA expression variations. A statistical analysis (P value ≤ 0.05) predicted 309 unique and mapped transcripts being significantly modulated between control and *Gata4*^{ΔIEC} indomethacin-treated




Figure 2. Claudin-2 expression is derepressed in the jejunum of *Gata4* mutant mice. (a) Total RNA was isolated from the jejunum of control and *Gata4*^{ΔIEC} mice (n = 3–4 per group) and RT-qPCR was performed to quantify claudin-2 gene transcripts. *****P* < 0.0001 (Student-t test). (b) Western blot analysis was performed using a claudin-2 polyclonal antibody on total lysates prepared from control and *Gata4*^{ΔIEC} mice. An actin polyclonal antibody was used as a loading control to monitor protein integrity. Cropped blots and full-length blots are included in the supplementary information. (c) Immunofluorescence detection of claudin-2 on jejunum sections prepared from control and *Gata4*^{ΔIEC} mice. Arrows display typical labeling in the tight junctions. Original magnification: 10X. (d) Schematic representation of the *Cldn2* gene with its predicted binding sites for GATA. (e–g) ChIP analysis of three paired biological samples (n = 3) obtained from the jejunum of control and *Gata4*^{ΔIEC} mice. Data were obtained by qPCR and are expressed as the percent of total DNA input used for precipitation with an antibody against Gata4 relative to the DNA precipitated with normal goat-IgG. **P* < 0.05 (ANOVA test). (h,i) ChIP analysis from the jejunum of control and *Gata4*^{ΔIEC} mice. Data were obtained by qPCR and are expressed as the percent of total DNA input used for precipitation with an antibody against H3K4me3 (h) or H3K27me3 (i) relative to the DNA precipitated with normal IgG.




Figure 3. Immune cells detection in the jejunum of *Gata4* mutant mice. T lymphocytes were visualized by immunohistochemistry against CD3 in control (a) and *Gata4* Δ IEC (b) mice. (c) The ratio of intra-epithelial lymphocytes (IEL) per total number of CD3 positive cells was averaged from 5 different crypt-villus axes of a total of 3 different mice per group. *** $P < 0.001$ (Student-t test). Macrophages were visualized by immunohistochemistry against CD68 in control (d) and *Gata4* Δ IEC (e) mice. (f) The total number of CD68 positive cells was averaged from 5 different crypt-villus axes of a total of 3 different mice per group. ** $P < 0.01$ (Student-t test). Original magnification 10X.

mice (differential ratio ≥ 2.0 ; Supplementary Table 3). To gain insight into how these modifications could be classified as biological meaning, we used the Ingenuity Pathway Analysis (IPA) software. This analysis identified the haematological system and cellular movement as being the top network functions affected in the *Gata4* Δ IEC indomethacin-treated mice. Disorders in nutrition (40 molecules; P value range between $8E-03$ and $5E-09$) and in inflammatory response (64 molecules; P value range between $9E-03$ and $3E-07$) were identified as the top affected diseases and biological functions. Death of epithelial cells was also predicted to be increased (26 molecules; P value of $8E-06$) (Supplementary Fig. 2) while immune cell trafficking (34 molecules; P value of $2E-04$)




Figure 4. Indomethacin severely impairs proximal small intestinal integrity of *Gata4* mutant mice. Control (a,c,e,g,i) and *Gata4* Δ IEC (b,d,f,h,j) mice were sacrificed 24 h after indomethacin injection and sections from the duodenum (a,b,g,h), the jejunum (c,d,i,j) and the ileum (e,f) were stained with H&E. Images are representative of at least 3 individuals per group. Original magnification: 2.5X (a–f) and 10X (g–j).




Figure 5. Expression of inflammatory modulators after indomethacin treatment of *Gata4* mutant mice. Total RNA was isolated from the jejunum of control and *Gata4*^{ΔIEC} mice that were sacrificed after indomethacin injection (n = 4–10 per group). RT-qPCR was performed to quantify MMP9 (a), S100A8 (b), TIMP1 (c) and Serpina1B (d) gene transcripts. ***P* < 0.01; ****P* < 0.001 (Student-t test).

was predicted to be decreased (Supplementary Fig. 3). These predicted changes in expression were next assessed for some candidate genes clustered among these networks of biological functions. A qRT-PCR analysis confirmed that matrix metalloproteinase 9 (MMP9) (2.4-fold reduction; *P* < 0.001) (Fig. 5a), S100 calcium binding protein A8 (S100A8) (2.1-fold reduction; *P* = 0.05) (Fig. 5b), tissue inhibitor of metalloproteinase 1 (TIMP1) (4.7-fold reduction; *P* < 0.001) (Fig. 5c) and Serpina1B (3.4-fold induction; *P* < 0.01) (Fig. 5d) gene transcripts were significantly modulated in the jejunum of *Gata4*^{ΔIEC} indomethacin-treated mice when compared to control indomethacin-treated mice. In accordance to the predicted decrease in blood cells movement, the number of CD3-positive T cells was lower in the jejunum of *Gata4*^{ΔIEC} indomethacin-treated mice (Fig. 6b) when compared to control treated mice (Fig. 6a). A similar observation was made for CD68-positive macrophages (Fig. 6c,d).

Discussion

The intestinal epithelial barrier integrity is critical to prevent the translocation of luminal components to the mucosa and to maintain the physiological and immunological homeostasis of the gut. In homeostatic conditions, pathogenic or environmental insults to the intestinal epithelium would stimulate the mucosal immune system and not necessarily lead to disease^{31,32}. However, a leaky gut barrier might both facilitate some level of constitutive inflammation and exacerbates the pro-inflammatory effects of the insults, given the increased exposure of the immune system to intruding luminal content that includes intestinal bacteria and their products. Our observations show that even though *Gata4* deficiency results in a compromised intestinal epithelial barrier, the small intestine remains free of overt inflammation. At first glance, this could appear contradictory. Indeed, several genetically engineered mouse models for which gut epithelial barrier function has been altered displayed defects in their mucosal immune response^{33–35}. However, one commonality among those models is that amplified immune response was mainly localized to the gut distal part. One possible explanation for these observations is the significant lower bacterial load in the jejunum because of higher antimicrobial activities when compared to the gut distal part³⁶. This could explain why *Gata4* mutant mice lack significant spontaneous inflammatory symptoms in the absence of nutritional or environmental stresses similar to what is observed for specific proximal gut disorders such as celiac disease³⁷.

The defect of barrier integrity as observed in the *Gata4* mutant mice is mechanistically linked to the direct interaction between *Gata4* and *Cldn2* transcription in the jejunum. Claudin-2 is well accepted to act by itself as a mediator of leaky gut barrier during intestinal inflammation⁹ as well as during exposure to microbial




Figure 6. Macrophages and T-lymphocytes mucosal distribution after indomethacin treatment of *Gata4* mutant mice. T lymphocytes were visualized by immunohistochemistry against CD3 in control (a) and *Gata4*^{ΔIEC} (b) indomethacin-treated mice. Macrophages were visualized by immunohistochemistry against CD68 in control (c) and *Gata4*^{ΔIEC} (d) indomethacin-treated mice (black arrows). The images were representative of 3 different mice per group. Original magnification: 10X.

products³⁸. *Gata4* was previously shown to stimulate transcription of a *Cldn2* promoter construct under artificial co-transfection assays in cultured cells³⁰. In contrast, our data indicate that deletion of *Gata4* leads to the activation of *Cldn2* promoter in the jejunum and a subsequent increase in claudin-2 expression. *Gata4* can act either as an activator or a repressor of gene transcription, depending on the nature of contextually-recruited co-regulators. Friend of Gata-1 (Fog-1) acts as a co-repressor of *Gata4* in the small intestine²⁰ and negatively regulates the expression of several genes including some members of the REG family²³. Whether Fog1 is functionally involved during *Gata4* dependent repression of *Cldn2* remains to be investigated, but our observations support a novel and global repressive role for *Gata4* in claudin-2 expression and barrier integrity in the context of an *in vivo* physiological system. How the increase in claudin-2 expression promotes mucosal permeability to FITC-dextran and *Salmonella* in *Gata4* mutant mice remains unclear. Claudin-2 forms a channel that is selectively permeable to small cations but not for molecules such as FITC-dextran or pathogens⁹. Whether the increase in claudin-2 expression alters other tight junction components or modifies the pattern of tight junction strands of intestinal epithelial cells in *Gata4* mutants are possible. Since no reduction in tight junction gene transcripts expression was observed in the jejunum of *Gata4* mutants and since ZO-1 protein distribution remains similar under these conditions (Supplementary Fig. 4), we postulate that the increase of claudin-2 and resulting changes in combination and mixing ratios of claudin molecules could influence the overall tightness of tight junction strands³⁹. In addition, increased gut permeability in these mice could also be caused by apoptosis resulting in epithelial cells loss.

NSAIDs are well described to cause damages to the human gastrointestinal tract but the exact mechanisms involved are not yet completely understood⁴⁰. Indomethacin treatment in mice often results in damage restricted to the more distal regions of the small intestine and will manifest after a relatively long period of time. Our findings that *Gata4* mutant mice become rapidly and highly sensitive to the deleterious effects of indomethacin in the proximal small intestine are, to our knowledge, unique and provide the opportunity to investigate in more detail the overall nature of the mechanisms involved during NSAID induced mucosal injuries. One interesting clue as to how *Gata4* might be involved in protecting the jejunum from such effects relates to the NSAID's potential to preferentially cause enteropathy by combination with bile⁴¹ and changes in the gut microbiota⁴². Intriguingly, bile acid absorption is induced in the jejunum of *Gata4* mutant mice²¹ and gut microbiota can inhibit bile acid reabsorption through *Gata4*²².

Although *Gata4* mutant mice did not show important spontaneous inflammation, their jejunum displayed minor but significant increases in IELs content. IELs are composed of a mixed population of lymphocytes and are believed to play an important role in protecting the epithelial barrier⁴³. Increase of their mucosal recruitment to a leaky barrier would make sense in this context. However, our data indicate that the jejunum of *Gata4* mutant mice is more prone to tissue damage following indomethacin treatment. It is tempting to speculate that subclasses of activated IELs might participate into the initial steps of deleterious damaging effects caused by

indomethacin as it is observed in the case of celiac disease⁴³. However, the transcriptome analysis coupled to the immunolocalization of immune cells in the jejunum of short-term indomethacin-treated *Gata4* mutant mice supports that the recruitment of immune cells and the inflammatory response are inhibited under these conditions. S100A8, abundantly expressed in immune cells of myeloid origin and thought to be functionally involved during epithelial wound healing of several tissues^{44,45}, was found to be decreased in injured mutant mice. MMP-9, an endopeptidase involved in wound healing through regulating the turnover of matrix proteins⁴⁶, was also found decreased under these conditions. It is intriguing that MMP-9 was found to be increased during the healing of indomethacin-induced small intestinal damage in rats and that administration of MMP inhibitors significantly impaired the healing of ulceration during this treatment⁴⁷. *Serpina1*, described as a potent blocker of hematopoietic stem cell mobilization⁴⁸, was found to be increased in injured mutant mice. It is also plausible that the jejunal epithelium of *Gata4* mutant mice be intrinsically less competent for epithelial restitution. In support of this, we recently reported that *Reg1*, a crucial factor for the maintenance of the villous structure of the small intestine²⁵, was spontaneously reduced in the jejunum of *Gata4* mutant mice²³.

Our study identifies *Gata4* as an epithelial transcriptional regulator crucial for the maintenance of physiological barrier integrity, as well as for the protection of the jejunal mucosa against epithelial injury. Few model systems are currently available to define the epithelial intrinsic contribution involved in proximal gut protection against inflammatory stimuli. For instance, specific transgenic mouse models with modified MHC class II molecules have been generated and showed to recapitulate some aspects of celiac disease pathogenesis when exposed to dietary gluten⁴³. Upon our analyses, *Gata4* deleted mice did not display classical signs of celiac disease associated signature, such as for instance, modification in the expression of IL-15 or activating natural killer receptor NKG2D gene transcripts (data not shown). Our findings open up on exploring whether *Gata4* and its regulatory network are involved in the pathogenesis and/or the protection against environmental damage and inflammatory diseases of the proximal gastrointestinal tract.

Methods

Animals. *Gata4*^{loxP26} and 12.4Kb *VilCre*²⁷ mice were used to generate 12.4Kb *VilCre/Gata4*^{+/+} (control) and 12.4Kb *VilCre/Gata4*^{loxP/loxP} (*Gata4*^{ΔIEC}) mice on a pure C57BL/6J background. Mice were kept under pathogen free conditions and were tested negative for *Helicobacter*, *Pasteurella* and murine norovirus. Some of the mice were injected a single dose of indomethacin (Sigma-Aldrich Canada Co., Oakville, ON) (10 mg/kg body weight) intraperitoneally and based on the observed severity phenotype for mutant mice, sacrificed 24 h later for tissue samples. Mice were treated in accordance with a protocol reviewed and approved by the Institutional Animal Research Review Committee of the Université de Sherbrooke (approval ID number 102-10B). The study followed the standards and policies of the Canadian Council on Animal Care in sciences.

RNA isolation and qPCR analysis. Total RNA was isolated from jejunum, ileum and colon mouse biopsies and subjected to a DNase treatment according to the manufacturer's instructions (Totally RNA kit, Life Technologies Inc., Burlington, ON). Reverse transcription and quantitative PCR (qPCR) were performed as described previously^{14,49} or were performed by the RNomics Platform at the Université de Sherbrooke (Sherbrooke, QC). Target expression was quantified relatively to porphobilinogen deaminase (PBGD) expression. Primer sequences used for qPCR are listed in Supplementary Table S4.

Electron microscopy. Mouse jejunum segments were prepared as reported before⁴⁹. Ultramicrotome-prepared thin sections were contrasted with lead citrate and uranyl acetate and then observed on a Jeol 100 CX transmission electron microscope.

Intestinal permeability *in vivo*. Permeability was assessed with the fluorescent isothiocyanate (FITC)-labeled dextran method as described previously⁵⁰. Mice were oral gavage with 60 mg/100g body weight of FITC-dextran (FD4, average molecular weight of 3,000–5,000, Sigma-Aldrich Canada Co., Oakville, ON) and sacrificed after 4 h. FITC concentration in the serum was quantified with a BioTek Synergy HT spectrometer plate reader (Winooski, VT) with excitation of the fluorophore at 492 nm and emission at 525 nm. Serum from mice not administered with FITC-dextran was used to determine the background.

Bacterial strain and mouse infections. *Salmonella enterica* serovar Typhimurium strain SB103 (*invA*) was grown overnight at 37 °C in LB supplemented with 100 μg/mL streptomycin. Inoculum was prepared in sterile HEPES 100 mM, NaCl 0.9%, pH 8.0. Mice were infected orally with 5×10^7 bacteria as previously described²⁹, and sacrificed after 3 days. For bacterial counts, tissues were homogenized, followed by plating of serial dilutions in LB plates containing 100 μg/mL streptomycin. All infections experiments were done in duplicate with a total of 5–6 mice per group.

Immunostaining. Immunofluorescence and immunohistochemistry staining was performed as previously described⁵¹. Non-specific binding was blocked and antibodies were diluted in PBS/Triton 0.05% solution containing 2% BSA (Sigma-Aldrich Canada Co., Oakville, ON). The following antibodies were used at the indicated dilutions: anti-PCNA (1:1000, Abcam), anti-CD3 (1:200, Dako), anti-CD68 (1:500, Aviva), FITC-conjugated anti-rabbit IgG (1:300, Santa Cruz), Alexa 568-conjugated anti-mouse (1:400, Invitrogen). For claudin-2 and ZO-1 immunodetection, 5 μm thick OCT cryosections were fixed in 100% methanol for 10 min at –20 °C and further processed for incubations with antibodies. Immunohistochemistry staining (DAB kit, Dako) was performed following the manufacturer's protocol.

Immunoblot analysis. Total protein extracts and western blots were performed as described previously⁵¹. The following antibodies were used: anti-claudin-2 (#51-6100, 1:500) (Invitrogen, Life Technologies Inc., Burlington, ON) and anti- β -actin (MAB1501R, 1:10,000) (EMD Millipore, Etobicoke, ON).

Chromatin immunoprecipitation assays. Chromatin immunoprecipitation assays (ChIP) were performed with the EZ-ChIP assay kit (EMD Millipore, Etobicoke, ON), according to the manufacturer's instructions. The jejunum was harvested from mice, cut opened in fragments and incubated in 1% formaldehyde for 15 min at 20 °C. Jejunum fragments were then rinsed twice with ice cold PBS/Glycine buffer and mucosal isolation was performed by scraping. Enriched mucosal fractions were weighed and a total of 40 mg was used for each condition. Mucosal fractions were chemically crosslinked by the addition of formaldehyde (1% final concentration) for 10 min at 20 °C, then lysed and sonicated to solubilize and shear crosslinked DNA to an average length of 200 base pairs. The cell extract was pre-cleared with 40 μ l Protein G magnetic beads (Life Technologies Inc., Burlington, ON) for 1 h and then, incubated at 4 °C overnight with 40 μ l Protein G magnetic beads and corresponding antibodies: 4 μ g of an isogenic immunoglobulin (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 4 μ g of GATA-4 affinity-purified polyclonal antibody (#SC-1237, Santa Cruz Biotechnology Inc., Santa Cruz, CA), 4 μ g of anti-Histone H3 (tri methyl K4) purified polyclonal antibody (#ab8580, Abcam, Toronto, ON) or 4 μ g of anti-trimethyl-Histone H3 (Lys27) purified polyclonal antibody (#07-449, EMD Millipore, Etobicoke, ON). Beads were washed twice with the provided buffers. Bound complexes were eluted from the beads by heating at 65 °C with occasional vortexing, and crosslinking was reversed by overnight incubation at 65 °C. A portion of the whole-cell extract DNA from the sonication step was also treated for crosslink reversal for input. Immunoprecipitated DNA and whole-cell extract DNA (1% input) were treated with proteinase K and RNaseA and then purified. Purified DNA was used as template for qPCR with a LightCycler apparatus V2.0 (Roche Diagnostics, Laval, QC). Sets of primers used to amplify GATA containing regions for *Cldn2* gene promoter and for a negative region from the *Il1 β* gene promoter are listed in Supplementary Table S5. Calculation of enrichment was performed using the $2^{-\Delta\Delta Ct}$ method that normalized ChIP DNA to input DNA and included signals obtained from both wild-type and *Gata4* ^{Δ IEC} mouse jejunum extracts²³.

DNA microarray and analysis. Probes for hybridization with Illumina BeadChips were generated from isolated jejunum RNA of three independent mice from both *Gata4* ^{Δ IEC} and control groups after 24 h of indomethacin treatment. The Illumina MouseWG-6 v2.0 Expression BeadChips were screened with the six generated probes via the McGill University and Génome Québec Innovation Center (<http://genomequebec.mcgill.ca>). FlexArray version 1.6.1 was used for data analysis (<http://genomequebec.mcgill.ca/FlexArray>). Genes were then filtered for up- or down-regulation of expression of a minimum of 2.0-fold and gene signature datasets analyzed by the Ingenuity Pathway Analysis tool (www.ingenuity.com).

References

- Tan, D. W. & Barker, N. Intestinal stem cells and their defining niche. *Current topics in developmental biology* **107**, 77–107, doi: 10.1016/B978-0-12-416022-4.00003-2 (2014).
- Turner, J. R. Intestinal mucosal barrier function in health and disease. *Nature reviews. Immunology* **9**, 799–809, doi: 10.1038/nri2653 (2009).
- Laukoetter, M. G., Bruewer, M. & Nusrat, A. Regulation of the intestinal epithelial barrier by the apical junctional complex. *Current opinion in gastroenterology* **22**, 85–89, doi: 10.1097/01.mog.0000203864.48255.4f (2006).
- Van Itallie, C. M. & Anderson, J. M. Claudins and epithelial paracellular transport. *Annu Rev Physiol* **68**, 403–429 (2006).
- Tamura, A. & Tsukita, S. Paracellular barrier and channel functions of TJ claudins in organizing biological systems: advances in the field of barrierology revealed in knockout mice. *Seminars in cell & developmental biology* **36**, 177–185, doi: 10.1016/j.semcdb.2014.09.019 (2014).
- Amasheh, S. *et al.* Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. *Journal of cell science* **115**, 4969–4976 (2002).
- Tamura, A. *et al.* Loss of claudin-15, but not claudin-2, causes Na⁺ deficiency and glucose malabsorption in mouse small intestine. *Gastroenterology* **140**, 913–923, doi: 10.1053/j.gastro.2010.08.006 (2011).
- Zeissig, S. *et al.* Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. *Gut* **56**, 61–72, doi: 10.1136/gut.2006.094375 (2007).
- Luettig, J., Rosenthal, R., Barmeyer, C. & Schulzke, J. D. Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation. *Tissue barriers* **3**, e977176, doi: 10.4161/21688370.2014.977176 (2015).
- Suh, E. & Traber, P. G. An intestine-specific homeobox gene regulates proliferation and differentiation. *Molecular and cellular biology* **16**, 619–625 (1996).
- Gao, N. & Kaestner, K. H. Cdx2 regulates endo-lysosomal function and epithelial cell polarity. *Genes & development* **24**, 1295–1305, doi: 10.1101/gad.1921510 (2010).
- Gao, N., White, P. & Kaestner, K. H. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. *Developmental cell* **16**, 588–599, doi: 10.1016/j.devcel.2009.02.010 (2009).
- Lussier, C. R., Babeu, J. P., Auclair, B. A., Perreault, N. & Boudreau, F. Hepatocyte nuclear factor-4 α promotes differentiation of intestinal epithelial cells in a coculture system. *American journal of physiology. Gastrointestinal and liver physiology* **294**, G418–G428, doi: 10.1152/ajpgi.00418.2007 (2008).
- Babeu, J. P., Darsigny, M., Lussier, C. R. & Boudreau, F. Hepatocyte nuclear factor 4 α contributes to an intestinal epithelial phenotype *in vitro* and plays a partial role in mouse intestinal epithelium differentiation. *American journal of physiology. Gastrointestinal and liver physiology* **297**, G124–G134, doi: 10.1152/ajpgi.90690.2008 (2009).
- Boudreau, F. *et al.* Hepatocyte nuclear factor-1 α , GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. *The Journal of biological chemistry* **277**, 31909–31917, doi: 10.1074/jbc.M204622200 (2002).
- Sumi, K. *et al.* Cooperative interaction between hepatocyte nuclear factor 4 α and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. *Molecular and cellular biology* **27**, 4248–4260, doi: 10.1128/MCB.01894-06 (2007).
- Battle, M. A. *et al.* GATA4 is essential for jejunal function in mice. *Gastroenterology* **135**, 1676–1686 e1671, doi: 10.1053/j.gastro.2008.07.074 (2008).

18. Bosse, T. *et al.* Gata4 is essential for the maintenance of jejunal-ileal identities in the adult mouse small intestine. *Molecular and cellular biology* **26**, 9060–9070, doi: 10.1128/MCB.00124-06 (2006).
19. Aronson, B. E. *et al.* GATA4 represses an ileal program of gene expression in the proximal small intestine by inhibiting the acetylation of histone H3, lysine 27. *Biochimica et biophysica acta* **1839**, 1273–1282, doi: 10.1016/j.bbagr.2014.05.018 (2014).
20. Beuling, E. *et al.* GATA4 mediates gene repression in the mature mouse small intestine through interactions with friend of GATA (FOG) cofactors. *Developmental biology* **322**, 179–189, doi: 10.1016/j.ydbio.2008.07.022 (2008).
21. Beuling, E. *et al.* Conditional Gata4 deletion in mice induces bile acid absorption in the proximal small intestine. *Gut* **59**, 888–895, doi: 10.1136/gut.2009.204990 (2010).
22. Out, C. *et al.* Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4. *Journal of hepatology* **63**, 697–704, doi: 10.1016/j.jhep.2015.04.030 (2015).
23. Lepage, D. *et al.* Identification of GATA-4 as a novel transcriptional regulatory component of regenerating islet-derived family members. *Biochimica et biophysica acta*, doi: 10.1016/j.bbagr.2015.10.011 (2015).
24. Cash, H. L., Whitham, C. V., Behrendt, C. L. & Hooper, L. V. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science* **313**, 1126–1130, doi: 10.1126/science.1127119 (2006).
25. Ose, T. *et al.* Reg I-knockout mice reveal its role in regulation of cell growth that is required in generation and maintenance of the villous structure of small intestine. *Oncogene* **26**, 349–359, doi: 10.1038/sj.onc.1209799 (2007).
26. Watt, A. J., Battle, M. A., Li, J. & Duncan, S. A. GATA4 is essential for formation of the proepicardium and regulates cardiogenesis. *Proceedings of the National Academy of Sciences of the United States of America* **101**, 12573–12578, doi: 10.1073/pnas.0400752101 (2004).
27. Madison, B. B. *et al.* Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. *The Journal of biological chemistry* **277**, 33275–33283 (2002).
28. Galan, J. E. & Curtiss, R. 3rd. Distribution of the invA, -B, -C, and -D genes of *Salmonella typhimurium* among other *Salmonella* serovars: invA mutants of *Salmonella typhi* are deficient for entry into mammalian cells. *Infection and immunity* **59**, 2901–2908 (1991).
29. Romain, G. *et al.* Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis. *BMC microbiology* **13**, 238, doi: 10.1186/1471-2180-13-238 (2013).
30. Escaffit, F., Boudreau, F. & Beaulieu, J. F. Differential expression of claudin-2 along the human intestine: Implication of GATA-4 in the maintenance of claudin-2 in differentiating cells. *Journal of cellular physiology* **203**, 15–26, doi: 10.1002/jcp.20189 (2005).
31. Su, L. *et al.* Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. *Gastroenterology* **136**, 551–563, doi: 10.1053/j.gastro.2008.10.081 (2009).
32. Pastorelli, L., De Salvo, C., Mercado, J. R., Vecchi, M. & Pizarro, T. T. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. *Frontiers in immunology* **4**, 280, doi: 10.3389/fimmu.2013.00280 (2013).
33. Vijay-Kumar, M. *et al.* Deletion of TLR5 results in spontaneous colitis in mice. *The Journal of clinical investigation* **117**, 3909–3921, doi: 10.1172/JCI33084 (2007).
34. Nenci, A. *et al.* Epithelial NEMO links innate immunity to chronic intestinal inflammation. *Nature* **446**, 557–561, doi: 10.1038/nature05698 (2007).
35. Kajino-Sakamoto, R. *et al.* Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. *Journal of immunology* **181**, 1143–1152 (2008).
36. Donaldson, G. P., Lee, S. M. & Mazmanian, S. K. Gut biogeography of the bacterial microbiota. *Nature reviews. Microbiology* **14**, 20–32, doi: 10.1038/nrmicro3552 (2016).
37. Verdu, E. F., Galipeau, H. J. & Jabri, B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. *Nature reviews. Gastroenterology & hepatology* **12**, 497–506, doi: 10.1038/nrgastro.2015.90 (2015).
38. Liu, X. *et al.* Microbial products induce claudin-2 to compromise gut epithelial barrier function. *PLoS One* **8**, e68547, doi: 10.1371/journal.pone.0068547 (2013).
39. Furuse, M., Furuse, K., Sasaki, H. & Tsukita, S. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. *The Journal of cell biology* **153**, 263–272 (2001).
40. Wallace, J. L. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. *British journal of pharmacology* **165**, 67–74, doi: 10.1111/j.1476-5381.2011.01509.x (2012).
41. Zhou, Y., Dial, E. J., Doyen, R. & Lichtenberger, L. M. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. *American journal of physiology. Gastrointestinal and liver physiology* **298**, G722–G731, doi: 10.1152/ajpgi.00387.2009 (2010).
42. Wallace, J. L. *et al.* Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. *Gastroenterology* **141**, 1314–1322, doi: 10.1053/j.gastro.2011.06.075 (2011).
43. Meresse, B., Malamut, G. & Cerf-Bensussan, N. Celiac disease: an immunological jigsaw. *Immunity* **36**, 907–919, doi: 10.1016/j.immuni.2012.06.006 (2012).
44. Dessing, M. C. *et al.* The calcium-binding protein complex S100A8/A9 has a crucial role in controlling macrophage-mediated renal repair following ischemia/reperfusion. *Kidney international* **87**, 85–94, doi: 10.1038/ki.2014.216 (2015).
45. Kerkhoff, C. *et al.* Novel insights into the role of S100A8/A9 in skin biology. *Experimental dermatology* **21**, 822–826, doi: 10.1111/j.1600-0625.2012.01571.x (2012).
46. Mott, J. D. & Werb, Z. Regulation of matrix biology by matrix metalloproteinases. *Current opinion in cell biology* **16**, 558–564, doi: 10.1016/j.ceb.2004.07.010 (2004).
47. Gyenge, M., Amagase, K., Kunimi, S., Matsuoka, R. & Takeuchi, K. Roles of pro-angiogenic and anti-angiogenic factors as well as matrix metalloproteinases in healing of NSAID-induced small intestinal ulcers in rats. *Life sciences* **93**, 441–447, doi: 10.1016/j.lfs.2013.07.021 (2013).
48. van Pel, M. *et al.* Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization. *Proceedings of the National Academy of Sciences of the United States of America* **103**, 1469–1474, doi: 10.1073/pnas.0510192103 (2006).
49. Boudreau, F. *et al.* Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **21**, 3853–3865, doi: 10.1096/fj.07-8113com (2007).
50. Coulombe, G. *et al.* Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. *Molecular and cellular biology* **33**, 2275–2284, doi: 10.1128/MCB.00043-13 (2013).
51. Darsigny, M. *et al.* Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. *PLoS One* **4**, e7609, doi: 10.1371/journal.pone.0007609 (2009).

Acknowledgements

The authors thank Pr. S.A. Duncan (Medical College of Wisconsin, Milwaukee, USA) for providing the *Gata4^{loxP}* mouse line, the McGill University and Génome Québec Innovation Centre for DNA microarray services, the RNomics Platform at the Université de Sherbrooke for qPCR services and the Electron Microscopy & Histology Research Core of the FMSS at the Université de Sherbrooke for histology and phenotyping services. This work was supported by the Natural Sciences and Engineering Research Council of Canada grant number 262094 (FB).

JB and JA were recipients of a FRQS fellowship. CA, NP, AM, FPG and FB are members of the FRQS-funded «Centre de Recherche du CHUS».

Author Contributions

D.L., É.B., C.J., S.T., J.A. and J.M.B. designed and performed the experiments, and analysed the results. F.P.G., C.A., A.M., N.P. and F.B. designed and supervised the work. F.B. wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Lepage, D. *et al.* Gata4 is critical to maintain gut barrier function and mucosal integrity following epithelial injury. *Sci. Rep.* **6**, 36776; doi: 10.1038/srep36776 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016